Abstract
Patients with Human epidermal growth factor receptor type 2 (Her2) overexpression are associated with aggressive tumor growth and poor clinical outcomes. Bispecific antibodies targeting Her2 have recently exhibited potent effects on Her2 signal inhibition. In this study, a novel biparatopic anti-Her2 bispecific antibody (Bp-Bs) was constructed by linking a single anti-CD3 Fab with two different anti-Her2 single-domain antibodies targeting non-overlapping epitopes of Her2. The Bp-Bs demonstrated strong binding on Her2-positive cells and potent cytotoxicity on Her2-positive tumor cells, even Her2-low expression cells, suggesting that biparatopic bispecific antibodies may have improved therapeutic benefits on broad Her2 patient populations.
Highlights
Human epidermal growth factor receptor type 2 (Her[2], named Her2/neu or ErbB2) is a member of the HER family of transmembrane receptor tyrosine kinases.[1]
The biparatopic anti-Her2 bispecific antibody (Bp-Bs) was formed via the heterodimerization of VH-CH1-VHH2 and VL-CL-VHH1, as anti-Her[2] VHH1 and anti-Her[2] VHH2 bind to different epitopes on Her[2] protein (Figure 1B)
The bivalent anti-Her2 bispecific antibody (Bi-Bs) was formed via the heterodimerization of VH-CH1-VHH1 and VL-CL-VHH1 (Figure 1A)
Summary
Human epidermal growth factor receptor type 2 (Her[2], named Her2/neu or ErbB2) is a member of the HER family of transmembrane receptor tyrosine kinases.[1]. The vital role of Her[2] in breast cancer development prompted therapeutic development targeting Her[2]. The development of the anti-Her[2] therapeutics trastuzumab, lapatinib, pertuzumab, and T-DM1 has achieved clinical benefits for Her2-positive patients.[9] low response rates and resistance are associated with current therapeutics. Only 15%–30% of Her2-positive patients respond to trastuzumab therapy due to de novo and acquired resistance.[10,11] Trastuzumab has minimal effects on Her[2] low- or medium-expression cancer cells in vivo and in vitro.[12,13] Poor internalization leads to resistance in T-DM1 treatment of metastatic breast cancer.[10,14,15] new therapeutic options are urgently needed for patients resistant to or with no response to current Her2-targeted therapies
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
